Quanterix Corporation (QTRX)
NASDAQ: QTRX · Real-Time Price · USD
2.895
+0.135 (4.89%)
Nov 6, 2026, 4:00 PM EST - Market closed
Quanterix Revenue
Quanterix had revenue of $32.91M in the quarter ending June 30, 2026, with 34.44% growth. This brings the company's total for the last twelve months to $153.41M, up 21.96% year-over-year. In the year 2025, Quanterix had annual revenue of $138.90M with 1.07% growth. That makes Quanterix the 19,439th largest company in the world by revenue and 3,039th in the United States.
Revenue (ttm)
$153.41M
Revenue Growth
+21.96%
P/S Ratio
0.89
Revenue / Employee
$340,909
Employees
450
Market Cap
136.91M
Revenue by Geography
- North America 85.11M 61.4%
- Europe, Middle East, and Africa (EMEA) 36.72M 26.5%
- Asia Pacific 16.82M 12.1%
Fiscal year ended Dec 31, 2025 See the full Quanterix breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 138.90M | 1.48M | 1.07% |
| Dec 31, 2024 | 137.42M | 15.05M | 12.30% |
| Dec 31, 2023 | 122.37M | 16.85M | 15.96% |
| Dec 31, 2022 | 105.52M | -5.03M | -4.55% |
| Dec 31, 2021 | 110.56M | 24.18M | 27.99% |
| Dec 31, 2020 | 86.38M | 29.64M | 52.25% |
| Dec 31, 2019 | 56.73M | 19.10M | 50.76% |
| Dec 31, 2018 | 37.63M | 14.76M | 64.52% |
| Dec 31, 2017 | 22.87M | 5.29M | 30.08% |
| Dec 31, 2016 | 17.59M | 5.41M | 44.38% |
| Dec 31, 2015 | 12.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Inogen | 355.06M |
| Neuronetics | 159.76M |
| RxSight | 121.83M |
| Owlet | 114.41M |
| Pulmonx | 88.78M |
| Apyx Medical | 59.57M |
| TriSalus Life Sciences | 45.08M |
| Nyxoah | 32.77M |
QTRX News
- 10 days ago - Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026 - Business Wire
- 26 days ago - Quanterix price target raised to $3.50 from $3 at TD Cowen - TheFly
- 4 weeks ago - Quanterix, Innovita announce NMPA approvals for SIMOA tech, testing - TheFly
- 4 weeks ago - Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals - Business Wire
- 6 weeks ago - Quanterix reports progress on Content Innovation Engine - TheFly
- 6 weeks ago - Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026 - Business Wire
- 7 weeks ago - Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Quanterix appoints Yuri Fesko as CMO - TheFly